



# The new levels of redox regulation of S-adenosylmethionine synthesis

**Title in Spanish:** *Los nuevos niveles de regulación redox de la síntesis de S-adenosilmetionina*

María Ángeles Pajares<sup>1,2\*</sup>

<sup>1</sup>Departamento de Metabolismo y Señalización Celular, Instituto de Investigaciones Biomédicas Alberto Sols (CSIC-UAM), Arturo Duperier 4, 28019, Madrid. <sup>2</sup>Grupo de Hepatología Molecular, Instituto de Investigación Sanitaria del Hospital Universitario La Paz (IdiPAZ), Paseo de la Castellana 261, 28046 Madrid.

**ABSTRACT:** S-adenosylmethionine is a very versatile compound known to be involved in as many reactions as ATP. Its role as methyl donor is key for the production of a large variety of molecules, as well as, for the modification of proteins and nucleic acids. Therefore, it is not surprising that impairments in the methionine cycle are found in many diseases including liver pathologies, Alzheimer or rare diseases. In most of these cases, reductions in S-adenosylmethionine concentrations correlate with the presence of oxidative stress. This fact prompted the study of a putative redox regulation of the methionine cycle that has been focused especially on methionine adenosyltransferases, the enzymes that synthesize S-adenosylmethionine. This review is intended to provide an outline of the new levels at which the redox control of these enzymes is exerted and their importance for liver pathology, a field in which we have made several key contributions.

**RESUMEN:** La S-adenosilmetionina es un compuesto muy versátil, conocido por participar en casi tantas reacciones como el ATP. Su papel como donante de grupos metilo es esencial para la producción de una gran variedad de moléculas, así como para la modificación de proteínas y ácidos nucleicos. Por ello, no resulta sorprendente que se hayan detectado alteraciones en el ciclo de la metionina en una gran variedad de patologías, que incluyen desde enfermedades hepáticas hasta el Alzheimer o enfermedades raras. En muchos de estos casos la reducción de los niveles de S-adenosilmetionina se acompaña de la presencia de estrés oxidativo. Este hecho ha inducido el estudio de una posible regulación redox del ciclo de la metionina, que se ha enfocado principalmente a las metionina adenosiltransferasas, que son las enzimas encargadas de la síntesis de S-adenosilmetionina. Esta revisión pretende dar una visión global de los nuevos niveles a los que se ejerce el control redox de estas enzimas y su importancia en hepatopatología, campo en el cual hemos realizado importantes aportaciones.

\*Corresponding Author: mapajares@iib.uam.es

Received: October 7, 2015 Accepted: June 27, 2016

Accésit Premio Real Academia Nacional de Farmacia del Concurso Científico 2015 de la Real Academia Nacional de Farmacia

An Real Acad Farm Vol. 82, N° 2 (2016), pp. 231-246

Language of Manuscript: English

## 1. INTRODUCTION

Nature has evolved to create several essential compounds with high versatility, so that a few molecules can be used in a large variety of reactions. Initially, this represents an evolutionary advantage reducing the number of enzymes and compounds required for life. However, this same aspect imposes a serious drawback, since alterations affecting these few processes may lead to disease. Among these versatile compounds two have been shown of special relevance for the cell, ATP and S-adenosylmethionine (SAM). This last metabolite was described for the first time in 1951 by Cantoni as an "active methionine" able to transmethylyate in the absence of ATP (1). Although at that moment its exact nature was unknown, in this same paper the author indicated that SAM was a product of the reaction between ATP and methionine. Finally, in 1953 this researcher described the reaction catalyzed by the "methionine activating enzyme" and the chemical nature of SAM (2).

The number and variety of biological processes that

involve the use of SAM has increased along the years, so that nowadays the catalogue of reactions using this metabolite is as large as that of the processes utilizing ATP (3). This versatility of SAM relies in its chemical structure, which contains a quiral sulfonium group through which carbon-sulfur bonds with aminopropyl, methyl and adenosine groups are established. These groups are donated to a large variety of substrates upon nucleophilic attack of the corresponding carbon-sulfur bond (reviewed in (4,5)). Additionally, SAM can also transfer the ribosyl or amino groups in processes that have been described in bacteria or plants (3,6,7).


Methyltransferases consume the majority of the SAM produced in any organism in reactions leading to the synthesis of small molecules (i.e. neurotransmitters, phosphatidylcholine, etc.), the modification of proteins (i.e. histones) and DNA, among others. The remaining SAM is involved in the synthesis of 5'-halogenated derivatives in marine organisms (adenosine group), queuosine (ribosyl group) and other hypermodified

nucleosides (3-amino carboxypropyl group), pelargonic acid (amino group), polyamines, molecules involved in bacterial signaling and ethylene (aminopropyl group). SAM can also be used both as cofactor or substrate by SAM radical proteins, which catalyze probably the last set of reactions involving this compound that has been identified to date (3,8). In mammals, transmethyations consume approximately 95% of the SAM produced and the rest is used for SAM decarboxylation, being decarboxylated SAM the genuine aminopropyl donor for the synthesis of the polyamines spermidine and spermine (4,9).

## 2. THE METHIONINE CYCLE IN MAMMALS

SAM synthesis is carried out by methionine adenosyltransferases (MATs; EC 2.5.1.6), also known as SAM synthetases, this step being the first and rate limiting of the methionine cycle (4) (Figure 1). Most of the information regarding this pathway has been obtained in liver, where a human adult processes up to 48% of the ingested methionine (9-11), but slowly information

concerning other organs is becoming available (i.e. the cochlea (12)). The need for increasing the existing knowledge in extrahepatic tissues has been emphasized when impairments of the methionine cycle, and especially reductions in SAM concentrations or hyperhomocysteinemia, have been associated with different pathologies. Most of the diseases in which alterations of the pathway have been demonstrated concern the liver (i.e. hepatitis, cirrhosis, acute liver failure, hepatocellular carcinoma) (9,13), but its impairment in cardiovascular diseases (14,15), Alzheimer (16-18), psoriasis (19), rare diseases (i.e. Wilson disease) (20-22) and even hearing loss (12,23) has been also shown. It is not surprising that such a variety of pathological states concur with an anomalous function of the methionine cycle, given not only the large diversity of biological processes involving SAM, but also the connections of this pathway with additional key routes and its dependence on the nutrient status, as will be explained below.



**Figure 1. Mammalian methionine cycle and associated pathways.** The scheme shows the main reactions involved in the methionine cycle, polyamine synthesis, folate cycle, trans-sulfuration and glutathione synthesis. A discontinuous blue line indicates the methionine salvage pathway. Enzymes and metabolites appear abbreviated as follows: MATs, methionine adenosyltransferases; PEAMT, phosphatidylethanolamine N-methyltransferase; GNMT, glycine N-methyltransferase; GAMT, guanidinoacetate N-methyltransferase; MTases, methyltransferases; SAHH, S-adenosylhomocysteine hydrolase; ADK, adenosine kinase; ADA, adenosine deaminase; CBS, cystathionine β-synthase; CTH, cystathionase; GCS, γ-glutamylcysteine synthetase; GSS, glutathione synthetase; GSR, glutathione reductase; BHMT, betaine homocysteine methyltransferase; BHMT2, betaine homocysteine methyltransferase 2; MTR, methionine synthase; DHFR, dihydrofolate reductase; SHMT, serine hydroxymethyltransferase; MTHFR, methylene tetrahydrofolate reductase; AMD, S-adenosylmethionine decarboxylase; THF, tetrahydrofolate; DHF, dihydrofolate; MTHF, 5-methyl tetrahydrofolate; MeTHF, methylene tetrahydrofolate; MTA, methylthioadenosine; GSSG, glutathione oxidized form; GAA, guanidinoacetate; X, any methyl acceptor.

Methionine was discovered in 1923 by Mueller (24),

and found to be essential for mammals in 1937, when

growth retardation was detected in rats fed methionine-free diets (25). Hence, this amino acid must be obtained from the diet, and after absorption, needs to be distributed to the whole organism, where requirements of each organ are not equal, as mentioned previously. Once into the cell the use of this amino acid is shared between protein synthesis and the methionine cycle, and part of the methionine consumed in these pathways can be recycled. Mammalian cells can recover part of the methionine used in the methionine cycle by homocysteine (Hcy) remethylation and also by the methionine salvage pathway, which has a minor role. Hcy remethylation requires additional methyl donors to synthesize methionine, being those mainly 5-methyl tetrahydrofolate (MTHF), but also betaine and S-methylmethionine (vitamin U). These remethylation reactions are catalyzed by a vitamin B12-dependent methionine synthase (MTR; EC 2.1.1.13), betaine homocysteine methyltransferase (BHMT; EC 2.1.1.5) and BHMT2 (EC 2.1.1.10), respectively (26,27). The Hcy required for this purpose is generated as an intermediate in the trans-sulfuration pathway that converts methionine into cysteine, and in which SAM synthesis by MATs is the first step. Transmethylation then use the methyl donor rendering the methylated products together with demethylated SAM, named S-adenosylhomocysteine (SAH). Three methyltransferases in charged of the synthesis of small compounds are the main consumers of hepatic SAM. Namely, glycine N-methyltransferase (GNMT; EC 2.1.1.20), phosphatidylethanolamine N-methyltransferase (PEMT; EC 2.1.1.17) and guanidinoacetate N-methyltransferase (GANMT; EC 2.1.1.2) which synthesize sarcosine, phosphatidylcholine and creatine, respectively (13).

The byproduct of transmethylation, SAH, is a potent inhibitor of most methyltransferases and its hydrolysis is carried out by SAH hydrolase (SAHH or AHCY; EC 3.3.1.1) in the only reversible reaction of the methionine cycle, which renders adenosine and Hcy (9). Elimination of SAH is key in order to maintain an appropriate methylation level that depends on the SAM/SAH ratio, also known as the methylation index. Calculations carried out in several tissues have established that the optimal hepatic ratio is approximately 4, although this number is higher for other tissues such as the lung, where the preferred methylation index is around 9 (28). Preservation of these optimal SAM/SAH ratios depends on an efficient removal of Hcy, adenosine or both.

Hcy levels depend on its catabolism through the remaining reactions of the trans-sulfuration pathway leading to cystathionine and cysteine, its elimination into the blood or, when methionine levels become low, its remethylation. The metabolic branch point represented by Hcy favors its use for cysteine synthesis through the consecutive activities of cystathionine  $\beta$ -synthase (CBS; EC 4.2.1.22) and cystathionase (CTH; EC 4.4.1.1). These two enzymes exhibit higher  $K_m$  values for Hcy than remethylating proteins, are activated by high levels of SAM and require vitamin B6 (26,29,30). In parallel,

adenosine can be utilized by adenosine deaminase (ADA; EC 3.5.4.4) or adenosine kinase (ADK; EC 2.7.1.20) to produce inosine or AMP, respectively (26). All these reactions connect the methionine cycle with multiple pathways in which regulators of the former are generated, hence creating a series of feedback loops whose complexity is not totally understood. Moreover, all the reactions described above do not show identical importance in every tissue, due to differences in gene expression patterns, and hence, on the enzymes or isoenzymes encountered in each cell type.

Main players in the regulation of the hepatic methionine cycle are metabolites, from the same or related pathways, hormones and nutrients, some of their key effects being summarized below. Among the metabolites, SAM deserves a special consideration, since its role includes the activation or inhibition of several enzymes such as MATs, CBS and CTH, as well as the inhibition of BHMT expression (29,31,32). SAM further contributes to the inter-regulation between pathways by inhibiting methylene tetrahydrofolate reductase (MTHFR; EC 1.5.1.20) of the folate cycle and regulating AMP kinase (AMPK; EC 2.7.11.31) phosphorylation (33,34). Nutrients such as vitamins of the B group, or their derivatives, also have a relevant role as cofactors or substrates for MTR, CBS and CTH, but also as inhibitors of GNMT in the form of MTHF (35-38). Moreover, methionine levels have been shown to regulate expression of MAT genes (39), and hormones seem to exert their role preferentially at the expression level, as occurs with glucocorticoids and MAT genes (40). Redox regulation is exerted by glutathione, and the ratio of its reduced (GSH) and oxidized (GSSG) forms (41-43), nitric oxide (44), hydroxyl radicals (45), NADP<sup>+</sup> (46), copper (20,47), etc. on MATs and SAHH. Additionally, oxidative stress inhibits MTR and activates CBS through changes in the redox status of their cofactors, vitamin B12 and the heme group, respectively (48).


### 3. METHIONINE ADENOSYLTRANSFERASES

MATs are a family of enzymes highly conserved between Bacteria and Eukaryota. This conservation expands from the amino acid sequence to the protein structure, facts that allowed us to propose MATs as a good phylogenetic marker back in 2004 (49). Moreover, MATs from Archaea despite their low sequence conservation (~18%) still preserve the amino acid residues involved in catalysis (50), suggesting that the mechanism for SAM synthesis has been maintained throughout evolution (5). This family of enzymes uses methionine and ATP as substrates in a reaction that requires Mg<sup>2+</sup> and K<sup>+</sup> ions and which takes place in two steps: 1) the transfer of the adenosyl moiety of ATP to the sulfur atom of methionine, generating SAM and triphosphate; and 2) the hydrolysis of the triphosphate originating pyrophosphate and inorganic phosphate and allowing SAM liberation from the active site (4,5).

There are three MAT genes in mammals, named *MAT1A*, *MAT2A* and *MAT2B*, which encode two types of

catalytic subunits, MAT $\alpha$ 1 and MAT $\alpha$ 2, and the regulatory subunit MAT $\beta$ , respectively (Figure 2). The high level of identity exhibited by MAT $\alpha$ 1 and MAT $\alpha$ 2 (85% at the amino acid level), is not shared by MAT $\beta$ , which is a non-related protein of the PFAM 04321

oxidoreductase family (4,5). Four splicing forms of MAT $\beta$  have been detected in hepatoma cells, from which the V1 form is the protein encountered in normal tissues and which has been evaluated in most studies published to date (51).



**Figure 2. Methionine adenosyltransferase nomenclature.** The scheme summarizes the nomenclature used in the field regarding genes, subunits, splicing forms (circled in green) and the oligomeric association of the subunits to render the isoenzymes found in the cytosol and the nucleus.

MAT subunits associate into the three isoenzymes that have been detected in mammalian cells, named MAT I, MAT II and MAT III (Figure 2). Their characterization was carried out after their isolation from liver (MAT I and III) or kidney (MAT II) and found to be homo- or hetero-oligomers (4). Precisely, MAT I and MAT III were identified as homo-tetramers and homo-dimers of MAT $\alpha$ 1 subunits (52-54), respectively, whereas MAT II was classified as a hetero-oligomer of MAT $\alpha$ 2 and MAT $\beta$  subunits (55,56). The affinity for methionine of the three isoenzymes expands the whole micromolar range (reviewed in (4,5)), some differences being encountered between laboratories, but mean data corresponding to the following values: 3  $\mu$ M for MAT II; 30  $\mu$ M for MAT $\alpha$ 2 homo-oligomers; 100  $\mu$ M for MAT I; and 1 mM for MAT III. In contrast,  $V_{\max}$  values showed the opposite trend, MAT II < MAT $\alpha$ 2 homo-oligomers < MAT I < MAT III. These kinetic parameters determine the capacity for SAM synthesis of each cell type, under normal or pathological conditions, according to the isoenzyme expressed and the level attained.

The classical knowledge on MATs by the 90s can be summarized as follows (reviewed in (4)): i) normal liver was the solely tissue where MAT1A was expressed; ii)

MAT2A was expressed in extrahepatic tissues, hepatopathologies and fetal liver; iii) MAT2B expression followed that of MAT2A, although at lower levels; iv) MAT isoenzymes were cytosolic proteins; v) MAT II was probably a heterotetramer ( $\alpha_2\beta_2$ ); v) binding of MAT $\beta$  to MAT $\alpha$ 2 increased the affinity of the latter for methionine; vi) SAM inhibits MAT I and II isoenzymes, but is an activator of MAT III; vii) MAT III is activated by dimethylsulfoxide; viii) cysteine residues were found to be important for MAT I/III activity and in order to maintain the association state; and ix) SAM was transported from the cytoplasm to other subcellular compartments as required. During my postdoctoral in Mato's group in the early 90s we were able to provide additional evidences concerning MAT I and MAT III (reviewed in (4). Those included results obtained both *in vitro* and *in vivo*, the main achievements being as follows: i) further insights into the role of the cysteine residues; ii) the modulation of the activity by glutathione levels; iii) regulation of the isoenzyme activity by PKC phosphorylation; iv) the identification of the putative ATP binding site by photoaffinity labeling; v) the regulation by glucocorticoids; and vi) the differential expression pattern during liver development. Based on these accumulated



knowledge, several questions remained unanswered, being their response the objective of our group in the last 20 years.


#### 4. OUR CONTRIBUTION TO UNDERSTAND MAMMALIAN METHIONINE ADENOSYLTRANSFERASES: FROM STRUCTURE TO NEW REGULATORY LEVELS

The objective since we started our independent work by 1994 was to understand several aspects of MAT regulation that were poorly addressed, despite the intensive work of several groups since their discovery. Some of the limiting facts for the field at that time related to the difficult purification procedures to obtain the isoenzymes and the lack of good antibodies or structural information. Therefore, our initial work was focused on these aspects to develop better protocols and tools that allowed progress in the study of MATs, and which latter favored additional studies on animal models, as will be explained below.

##### 4.1. Association of $\alpha$ -subunits is required to obtain active MATs

The first objective of our work was to understand the need for oligomerization of MAT  $\alpha$ -subunits, and for this purpose we undertook the crystallization of rat MAT I and MAT III. Our initial attempts were based in the use of the rat liver purified proteins, but the heterogeneity of the

sample precluded crystallization. Next, we tried to use the recombinant protein overexpressed in *E. coli* (53,54), and several important problems had to be faced: 1) the level of soluble protein was very low; 2) it was impossible to separate the recombinant protein from the bacterial MAT due to their high homology and identical chromatographic behavior; and 3) refolding of MAT I/III from the inclusion bodies required a protocol that had to be established. Nevertheless, we decided to pursue the design of a specific refolding protocol (57), rendering large amounts of soluble protein, and that latter revealed its use for additional purposes. The success of this refolding protocol relied on the use of very low protein concentrations, the addition of  $Mg^{2+}$  to the buffers, the utilization of two refolding steps (fast and slow), and the maintenance of the 10 cysteines of rat MAT $\alpha$ 1 in a reduced state during the whole procedure (57). Characterization of the refolded protein showed that both MAT I and MAT III isoenzymes could be obtained, and their interconversion was possible just by concentration or dilution of the sample (57). Moreover, kinetic parameters and circular dichroism spectra of the refolded proteins were similar to those of the isoenzymes purified from rat liver (57,58). These facts, together with the large amount of refolded and purified MAT I/III obtained, led us to use these proteins in new crystallization attempts that were successful.



**Figure 3. Structural details of MAT $\alpha$ 1 and its dimer.** A cartoon representation of the secondary elements found in rat MAT $\alpha$ 1 monomers is shown in the upper left panel. An arrow indicates the position of the flexible loop of access to the active site in the completely folded subunit and the central domain is highlighted. The crystal structure of the MAT III appears on the right side of the figure, an arrow indicating the entrance to the active site located at the dimer interface. The lower part of the figure shows a magnification of the central domain, including the five cysteine residues located in this area (C35, C61, C57, C67, C105). The position of the intrasubunit disulfide (C35-C61) appears indicated by a circle.

The crystal structure of rat MAT I was reported in 2000, becoming the first mammalian structure solved for this family of proteins (59). MAT $\alpha$ 1 monomers showed a three-domain organization similar to that previously

described for the *E. coli* counterpart (5) (Figure 3). The domains were formed by nonconsecutive stretches of the protein chain, each of them containing a  $\beta$ -sheet (59). The three sheets made up a large hydrophobic surface that

constituted the interaction interface between monomers in the dimer. The two active sites of each dimer located at this interface, opposite one to another, and their structure required residues of both subunits for catalysis (59,60). This organization therefore explained the need for association exhibited by MAT $\alpha$ 1 subunits, and the fact that dimers were the minimum active isoenzymes. Production of the crystals in the presence of substrates or certain analogues also allowed the identification of key residues for catalysis (59,60). Precisely, F251 was identified as key for methionine binding (59), whereas the role in ATP binding of a P-loop previously identified by photoaffinity labeling was confirmed (60,61). The next level of association involved the central domains of each monomer, which provided the few residues that allowed tetramerization, being the resulting interaction pattern much more limited than that previously described for *E. coli* MAT (62). How these interactions contribute to the changes in affinity and  $V_{\max}$  shown between MAT I and MAT III is still unknown and requires further investigation.

#### 4.2. Interconversion between MAT I and III isoenzymes is blocked by an intrasubunit disulfide bond

The next question we addressed concerned the interconversion between MAT I and MAT III, and specifically what blocks this exchange, which is not observed in the liver purified isoenzymes. The sequence of MAT $\alpha$ 1 includes 10 cysteine residues and N-ethylmaleimide modification of just one of them was responsible for a large loss of enzymatic activity. Moreover, modification of an additional sulfhydryl group led to inactive dimers (63). Analysis of mutants generated in all the cysteines confirmed the role of these residues in activity, and demonstrated that those comprised between C35 and C105 were involved in the control of the MAT III/I isoenzyme ratio (64). Latter on, C121 was identified as the target for inactivation by nitric oxide and hydroxylation (44,45,65), a role explained by its location in the loop of access to the active site (59,60). However, our initial studies using chemical modification also revealed that in the isoenzymes purified from rat liver two cysteine residues remained elusive, and that only after reduction they became accessible to N-ethylmaleimide modification (63,66). These data suggested the presence of a disulfide bond within MAT I and MAT III, which was identified as an intrasubunit bond involving C35 and C61 in the isoenzymes isolated from rat liver (66) (Figure 3). The crystal structure of MAT I, obtained under reducing conditions, showed that these residues were well oriented and at a distance short enough to form such an intrasubunit bond (59).

The role of the disulfide was further explored taking advantage of the available refolding procedure and cysteine mutants prepared on MAT $\alpha$ 1 (62). For this purpose, refolding was carried out under reduced (with DTT) or mild oxidative conditions (with GSH/GSSG mixtures). Analysis of the resulting refolded isoenzymes

showed that interconversion between MAT I and MAT III could be produced only when the proteins were fully reduced (62). Moreover, mass spectrometry evaluation of the refolded proteins revealed that this interconversion was blocked by the presence of the C35-C61 disulfide bond in the isoenzymes resulting from refolding under mild oxidative conditions (62). Once more, the use of the available structural data allowed us to propose that the role of this intrasubunit disulfide relies in its ability to stabilize the  $\beta$ -sheet of the central domain involved in dimer-dimer interactions. Therefore, production of the disulfide at different steps during folding would result in stable tetramers or dimers.

#### 4.3. Unfolding of MAT I and MAT III takes place through an intermediate state

Our two-step refolding protocol suggested the requirement of an intermediate state that must be well populated to obtain a correct association pattern of the MAT $\alpha$ 1 monomers into dimers, in order to avoid aggregation (57). Unfolding studies carried out on MAT III using urea as denaturant confirmed this hypothesis, and demonstrated a three-state mechanism that is reversible (58). The intermediate identified by gel filtration chromatography and sedimentation velocity was an inactive monomer with 70% of the native secondary structure, according to circular dichroism results. Moreover, the instability exhibited by the dimer in the presence of the denaturant was due to its dissociation, probably by weakening of the interface interactions between MAT $\alpha$ 1 monomers. In fact, we were able to calculate that approximately 50% of the global stabilization energy of MAT III was due to subunit association, whereas only 25% derived from the interactions stabilizing the intermediate state. MAT I unfolding was also studied taking advantage of the differences in fluorescence intensity exhibited by tetramers and dimers upon 8-anilino-1-naphthalene-sulfonic acid (ANS) binding. The results obtained suggested that around 65% of the global free energy derives from dimer dissociation, thus supporting a lower stability for dimer-dimer interactions (62). On the other hand, thermal denaturation of MAT I and MAT III was shown to be irreversible, regardless of the techniques used to follow the process. Only one transition was observed for both tetramer and dimer denaturation, hence suggesting that stability of MAT I is highly dependent on that of the dimer (67). Using two-dimensional infrared spectroscopy and the structural data it was possible to ascribe the earliest changes to the most exposed elements,  $\alpha$ -helices and  $\beta$ -turns.

The high level of sequence and structural conservation among  $\alpha$ -subunits suggested no large differences in folding pathways for MAT $\alpha$ 1 and MAT $\alpha$ 2 monomers, although association steps may diverge due to the incorporation of MAT $\beta$  into MAT II hetero-oligomers. However, this initial hypothesis was demonstrated to be partially wrong when refolding of MAT $\alpha$ 2 was performed.

In fact, this subunit followed a similar pathway to produce MAT $\alpha$ 2 dimers, and only in a latter step association of MAT $\beta$  takes place (46). Data regarding folding pathways *in vivo* remain very limited, although *E. coli* MAT was identified several years ago among the substrates for the chaperonin GroEL (68).

All this information regarding folding and structure could be of help to understand the impact of the different *MAT1A* mutations detected in patients with isolated persistent hypermethioninemia, and in fact we performed this exercise in 2011 (69). Most of these patients are asymptomatic, although demyelination and other central nervous system manifestations have been described in several cases (70,71). The number of patients is still small, but newborn screenings in search for CBS defects are aiding in the identification of hypermethioninemias due to *MAT1A* mutations. Most mutations follow a recessive autosomal inheritance trait, although a dominant pattern has been described for the transition leading to the R264H protein mutant (72). The presence of early stop codons leading to shorter MAT $\alpha$ 1 subunits has been reported, as well as the possibility of longer chains due to mutations in the stop codon or splice-donor sites (70,71,73). Analysis of some of these mutant proteins has been carried out upon overexpression in *E. coli* and/or COS cells and their effects on activity evaluated. The early stop codons identified to date lead to proteins lacking from part (386X) or most (350X) of the C-terminal domain, to others in which even information for a complete domain is absent (92X and 185X). Additional early stop codons (351X) result not only in the loss of half of the C-terminal domain, but also in a change of sequence that affects a portion of the central and the remaining C-terminal domains. In contrast, longer subunits resulting from the stop codon mutation (X396Y-464X) present with the whole wild type sequence, and hence the information for the whole N- and central domains plus and extended C-terminal domain. Longer monomers due to splice-donor mutations on exon III, will result in proteins whose sequence is drastically altered, and hence, their folding and structure. If not eliminated by proteolysis, the shortest MAT $\alpha$ 1 subunits are expected to result in a complete change in the folding pattern, precluding association. However, those mutants in which the sequences for the N- and central domains remain intact, and even part of the C-terminal domain is preserved, may achieve an intermediate state that allows association (69).

This is the case for mutations leading to MAT $\alpha$ 1 subunits of approximately 350 residues, which were the first identified in patients with demyelination. In fact, Hazelwood *et al.* proposed that this type of subunits might associate with MAT $\alpha$ 2 monomers, leading to an inactive hetero-oligomer (74). Although plausible, given the high level of sequence identity between MAT $\alpha$ 1 and MAT $\alpha$ 2 subunits, the availability of new structural data showed

that there are small differences in the orientation of the monomers. Moreover, these mutants ~350 residues long lack the C-terminal domain sequence involved in the monomer-monomer interface, including the  $\beta$ -sheet that participates in dimer association. These divergences together will impose a rearrangement to avoid exposure of amino acids that are hidden in the wild type MAT $\alpha$ 1, and hence reducing the probability of association with MAT $\alpha$ 2 (69). Once again, additional experiments are needed for verification of the folding pathways followed by the mutants, their putative ability to hetero-oligomerize with wild type subunits, etc.

#### 4.4. Oxidative stress induced by copper accumulation impairs SAM synthesis in early stages of Wilson disease

Several models of liver disease that induce oxidative stress by different mechanisms have been explored along the years regarding the alterations induced in SAM synthesis. Just to name some, carbon tetrachloride intoxications (75,76), treatments with buthionine sulfoximine (BSO) (42), Long Evans Cinnamon (LEC) rats (20-22), etc. all concur with a reduction in MAT activity and SAM levels. Now that the role of cysteines in MAT I and MAT III is known this is no longer a surprise, but since most of these models were explored earlier there was a need to revisit certain aspects. Among them, the case of the Wilson disease model provided by LEC rats remained underexplored, probably because of the rare condition of this pathology. The available data referred only to activity parameters and were determined in an advanced stage of the disease, where hepatitis was already present. Therefore, we decided to explore early pathological stages to get insight into the copper effects on SAM synthesis. For this purpose, we examined 9-week old LEC rats, which already presented with copper deposits in the liver, but no signs of hepatitis (20).

Hepatic copper accumulation at this early step led to changes in expression that were unexpected for MAT genes (20). The *Mat1a/Mat2a* expression switch was already detected in LEC rats at this age, but *Mat2b* expression was dramatically reduced, hence following an opposite pattern to that classically described in liver disease. These effects on *Mat2b* expression were prevented by neocuproine, a chelator of Cu (I) (Figure 4). Reductions in SAH concentrations were larger than effects on SAM levels, probably due to the effects of copper on SAHH (47). Activity measurements carried out under conditions that allowed distinction between the three MAT isoenzymes indicated a decrease in MAT III activity, together with an increase in the combined activity of MAT I and MAT II. These effects on activity correlated with an enhancement in the MAT I content together with a reduction in that of MAT III, according to analytical gel filtration chromatography (AGFC) and dot blot detection of MAT $\alpha$ 1 (20).





liver disease (4,13,79,80). Moreover, the *Mat1a*<sup>-/-</sup> mouse developed severe hepatic pathology with age, most of these mice showing hepatocellular carcinoma (81). In contrast, most patients with hypermethioninemia due to mutations in this same gene either do not develop symptoms or those are neurological, including a few cases showing signs of demyelination by magnetic resonance imaging (MRI), as explained in a previous section (70,71,82). Therefore, in our opinion, there was a need to reexamine the tissue expression profile of *MAT1A*. Using real-time RT-PCR this analysis was performed in rat tissues, where expression was detected in almost all of those examined. Several expression levels were found: 1) high, shown in liver; 2) medium, exhibited by pancreas and lung; and 3) low, found in the rest of the tissues examined (83). This same pattern was further confirmed by western blot using an anti-MAT $\alpha$ 1 antibody developed in the last years in our laboratory using highly purified preparations of the protein (64,83).

#### 4.7. MATs are cytoplasmic and nuclear proteins

Localization of MATs to the cytoplasm was a well-established characteristic, based mainly in traditional subcellular fractionation studies and activity measurements. However, lack of good antibodies precluded confirmation of this statement for a long time. Again, using the new available antibody and immunohistochemistry we were able to detect MAT $\alpha$ 1 in both the cytoplasm and the nucleus, although nuclear localization was preferred in extrahepatic rat tissues (83). This discovery led to new questions regarding whether there was nuclear MAT activity and which were the isoenzymes present in that subcellular compartment. The answer to these points required the development of improved subcellular fractionation protocols and activity measurements that allowed not only detection of the small amount present in the nucleus, but also, and more important, to guarantee lack of contamination from the cytoplasm. In order to detect nuclear MAT activity, a highly concentrated nuclear extract from a whole rat liver was required, together with 4-fold increased levels of the radioactive tracer and longer reaction times. In parallel, LDH activity was measured to ensure complete elimination of the cytoplasm, and even more critical, the activity measurements (LDH and MAT) were carried out in the supernatant before nuclear protein extraction to ensure that the detected activity was specific of the nuclear compartment. Following this protocol, the specific MAT activity detected in the nucleus was approximately 250-fold lower than in the cytoplasm (83). Regarding the nuclear isoenzymes, AGFC followed by dot-blot detection of MAT $\alpha$ 1 showed the protein as tetramers and monomers, the amount of MAT I being small (83). Therefore, the low nuclear MAT activity measured correlated with the presence of equivalent levels of MAT I in this compartment.

#### 4.8. Overlapping areas of the C-terminal end are involved in the subcellular distribution of MAT $\alpha$ 1

SAM is a small compound that can be transported through the nuclear pore, but this structure limits the size of the proteins that can be translocated from one side to another of the nuclear membrane to near 50 kDa. This is almost the size of MAT  $\alpha$ -subunits and is far below that of MAT I (180 kDa). Thus, understanding how MAT $\alpha$ 1 is distributed between the nucleus and the cytoplasm was our next objective. Many nuclear proteins present localization signals (NLSs) in their sequence (84), others contain conformational signals that mimic the classical NLSs (85), and in other cases binding to proteins including appropriate signals is preferred (piggy-back)(86). Among NLSs, the best-known or classical signals are mono- and bi-partite sequences rich in basic residues, for whose identification several bioinformatic tools are available. Using this software we were unable to identify a classical NLS in the rat MAT $\alpha$ 1 sequence, and hence the crystal structure was utilized to determine the existence of exposed clusters of basic residues that could mimic such NLSs. Our analysis revealed that the C-terminal of MAT $\alpha$ 1 is abundant in basic residues, and those exposed to the surface were selected for site-directed mutagenesis. The subcellular distribution of the mutants was analyzed by confocal microscopy and subcellular fractionation and the combined results allowed the identification of two overlapping areas in the monomer structure that were involved either in nuclear localization or cytoplasmic retention (83).

Subcellular localization was independent of MAT activity, since an inactive mutant prepared on a residue involved in methionine binding (F251D) showed the same distribution than the wild type protein (83). Moreover, deletions at the C-terminal end, similar to those found in some patients showing demyelination (lacking 45 residues), favored nuclear localization of the truncated MAT $\alpha$ 1 (83). Additionally, it was demonstrated that nuclear localization of MAT $\alpha$ 1 correlated with increased levels of the trimethylation of lysine 27 in histone 3 (me3K27H3) (83), a well-known epigenetic repression mark. In contrast, other histone methylations examined were increased by overexpression of MAT $\alpha$ 1, independently of the subcellular distribution observed for the mutants.

In 2011, MAT $\alpha$ 2 was also found in the nucleus during a proteomic analysis in search for protein-protein interactions of the MafK transcription factor (87). This study showed MAT $\alpha$ 2 acting as a transcriptional corepressor of MafK on the heme oxygenase 1 (HO-1) gene. Moreover, a role for MAT $\beta$  and MAT activity in this repression system was described. This manuscript together with an Editorial in the same issue of Molecular Cell (87,88), supported the hypothesis, previously postulated by our group (83), suggesting that MATs are transported to nuclear locations where SAM synthesis is needed, whereas organelles such as the mitochondria use transport systems to obtain the compound from the cytoplasm.

#### 4.9. Nuclear accumulation of MAT $\alpha$ 1 is induced during


### acute liver injury

The results described in the previous section suggested that changes in MAT $\alpha$ 1 subcellular distribution might be related to disease development. In order to examine this possibility, we choose two rat models of acute liver injury that were previously used for partial characterization of alterations in cytosolic methionine metabolism (89-91). Precisely, D-galactosamine and paracetamol intoxications were known to induce reductions in MAT activity and SAM levels (89,90,92). These changes in the D-galactosamine model were ascribed to an anomalous ratio of the MAT isoenzyme activities towards enhanced MAT III activity (89,90). We were able to reproduce these previous results in the cytosol, reductions in total MAT activity being more modest for paracetamol than for D-galactosamine treatments (92,93). The mechanism of action of both drugs is quite different, D-galactosamine inducing depletion of the uridine pool (94), and thus highlighting the interest of analyzing putative expression changes in that model. After 48 hours of D-galactosamine treatment, changes in the mRNA levels of most genes in the methionine cycle were evident, namely: i) the *Mat1a/Mat2a* expression switch, followed by a more modest increase in *Mat2b* expression; ii) increased mRNA levels for *Ahcy* and *Mtr*; iii) enhanced expression of genes involved in glutathione synthesis; and iv) decreased expression of *Gnmt* and *Bhmt* (93). In general, genes considered "exclusively hepatic" showed lower expression.

Additional analyses carried out showed that the changes induced by D-galactosamine in the cytosolic protein levels of MAT $\alpha$ 1, BHMT, SAHH and GNMT closely matched the alterations observed in their expression (93). Focusing specifically on MAT $\alpha$ 1, the protein levels were reduced by ~50%, this decrease

correlating with a severe alteration in the isoenzyme pattern according to AGFC profiles, where only a small amount of MAT III was detected (93)(Figure 5). Altogether these results followed the previously published pattern detected by activity measurements in the cytosol (89). Paracetamol intoxication produced a more modest decrease in cytosolic MAT $\alpha$ 1 protein levels together with a completely different pattern in the MAT isoenzyme profile by AGFC, where an increase in MAT I content was readily observed. Moreover, while the MAT III/I activity ratio increased in the cytosol of paracetamol treated livers, the opposite trend was followed by the protein ratio, thus suggesting a certain degree of inactivation of MAT I in these samples (93).

Analysis of the nuclear effects of the treatments revealed accumulation of MAT $\alpha$ 1 in this compartment both by D-galactosamine and paracetamol intoxications (93). AGFC revealed increased levels of MAT I and a reduction in those of MAT $\alpha$ 1 monomers in nuclear fractions of D-galactosamine-treated livers, which correlated with the detection of enhanced nuclear MAT activity (Figure 5). In contrast, paracetamol induced a modest increase in nuclear MAT I levels, but no significant changes in activity were measured. However, in both models enhanced levels of the me3K27H3 repression mark were also detected. This lack of correlation between activity and the histone modification in paracetamol intoxication prompted us to evaluate nuclear SAM levels. However, the procedures needed to purify nuclear fractions precluded this measurement, given the exchange through the nuclear pore that takes place during the extensive washing steps required for isolation. These measurements will be only possible when appropriate imaging techniques become available.



**Figure 5. Summary of the effects detected in animal models of acute liver injury.** A schematic representation of the hepatic changes induced by acute D-galactosamine and paracetamol intoxications on glutathione levels, MAT $\alpha$ 1 subcellular localization and a repression signal in liver are depicted. The preventive effects of N-acetylcysteine (NAC) are also shown.

4.10. Changes in the ratio between reduced and oxidized glutathione forms controls the nucleocytoplasmic

distribution of MAT $\alpha$ 1.

D-galactosamine and paracetamol are known to induce

redox stress and to reduce the GSH/GSSG ratio. Although the mechanism by which D-galactosamine exerts this effect seems rather indirect, this is not the case for paracetamol, whose detoxification requires GSH consumption, thus leading to altered GSH/GSSG ratios (94). As mentioned previously, my own work demonstrated in 1992 that MAT I and MAT III activities were modulated by the GSH/GSSG ratios and, at extreme concentrations of GSSG, even the association state was modified (41). Therefore, we decided to explore whether glutathione ratios exerted an additional role in the control of MAT $\alpha$ 1 subcellular distribution using a cellular system, which allowed multiple combinations of drugs. Available hepatic cell lines include hepatomas and iPS-hepatocytes with low or no *MAT1A* expression (79,95), and primary cultures of hepatocytes rapidly loose expression of this gene (40,96). Therefore, transfection was needed to explore MAT $\alpha$ 1 behavior in any of these systems, among which we chose the hepatoma H35 cell line for overexpression of tagged-MAT $\alpha$ 1 (93). D-galactosamine treatment in this system reproduced the changes detected in the rat model: i) reduction in the GSH/GSSG ratio; ii) decreased cytosolic levels of MAT $\alpha$ 1; iii) accumulation of MAT $\alpha$ 1 in the nucleus; and iv) increase of the me3K27H3 signal. Agents that serve as sources of cysteine for glutathione synthesis, N-acetylcysteine (NAC) and SAM, were then combined with D-galactosamine treatment and their preventive effects evaluated (Figure 5). Among them, only NAC was effective in preventing all the changes induced by the drug (93).


In this same cellular system the effects induced by paracetamol in the rat model were also reproduced, namely: i) GSH depletion with the concomitant decrease in the GSH/GSSG ratio; ii) nuclear accumulation of MAT $\alpha$ 1; and iii) increased levels of the me3K27H3 repression mark. However, in this case the combination of paracetamol with NAC only prevented effects on glutathione levels and MAT $\alpha$ 1 localization, whereas me3K27H3 levels remained elevated (93). Further confirmation of the role of GSH/GSSG ratio in the regulation of MAT $\alpha$ 1 subcellular distribution was obtained using BSO, a compound that inhibits glutathione synthesis. Again, BSO treatment reduced the GSH/GSSG ratio and nuclear MAT $\alpha$ 1 accumulation was induced in the cells, these effects being prevented by addition of glutathione ethyl ester (93). Differences between D-galactosamine and paracetamol intoxications may relay not only in their effects on glutathione levels, but also in the ability of the paracetamol intermediate NAPQI for protein modification. Such modification involves again sulphydryl

groups, which are essential for MAT I and MAT III function, and hence additional studies are required to address this aspect.

## 5. INTEGRATED FOR MATs AND FUTURE RESEARCH MODEL OF REDOX REGULATION

Altogether the available data concerning redox regulation of MATs expand from expression to subcellular localization and were summarized in a hypothesis recently proposed by our group (97) (Figure 6). This new theory expands a previous proposal that we made back in 1992 (98), by adding the accumulated knowledge obtained in these years. Since the purpose of this review is not to revisit these hypotheses, only a few data will be highlighted.

Most efforts in the last decades have been concentrated in understanding the regulation of *MAT* expression, rendering information from transcription factors acting on the promoter (i.e. NF $\kappa$ B), the different gene methylation levels according to the liver state, stabilization of the mRNAs (i.e. AUF1 and HuR binding), etc. Our own work has been concentrated however in the proteins themselves, our results concerning from the structure (i.e. intrasubunit disulfide bond), to cofactor regulation (i.e. NADP<sup>+</sup> binding) and, more recently, subcellular distribution of MAT $\alpha$ 1 and its relationship with disease. Briefly, the proposal indicates that the high SAM levels found in normal liver depend on: 1) low methylation levels of the *MAT1A* promoter allowing gene expression; 2) high *MAT2A* promoter methylation levels, together with decreased *MAT2A* mRNA stability by binding of meHuR; 3) the normal ratios of GSH/GSSG preserving high MAT I/III activity in the cytosol and keeping MAT $\alpha$ 1 transport to the nucleus at low ratios, therefore maintaining adequate methylation levels of histones and DNA. In contrast, the low SAM levels found in damaged liver are due to the combination of: 1) an inversion of the promoter methylation levels, which become high for *MAT1A* and low for *MAT2A* promoters; 2) enhanced *MAT2A* and *MAT2B* transcription by the action of redox regulated transcription factors; 3) destabilization of *MAT1A* mRNA by AUF binding, together with stabilization of *MAT2A* transcripts by HuR binding; 4) increased oxidative stress leading to higher levels of NADP<sup>+</sup> and reduced GSH/GSSG ratios, which together favor cytosolic MAT II accumulation, the low V<sub>max</sub> MAT; and 5) reduced GSH/GSSG ratios induce nuclear accumulation of MAT $\alpha$ 1 and MAT I providing higher nuclear SAM concentrations for epigenetic mechanisms.



**Figure 6. Actualized version of the model proposed for redox regulation of MATs.** The proposal includes the most significant data regarding normal liver (left) and damaged liver (right). Mean GSH/GSSG ratios in each situation are included, together with the changes detected in expression due to gene methylation or stabilization/destabilization of the mRNAs. Effects on the proteins include those derived from increased levels of the cofactors, altered association patterns and subcellular distribution rendering finally, high or low SAM levels in normal and damaged livers respectively.

Redox regulation is probably the best-known mechanism controlling MAT function in disease states, but still questions regarding how copper exerts its effects on these enzymes remain unsolved. Additionally, the role of other actors in redox stress, such as  $\text{NAD}^+/\text{NADH}$  or  $\text{NADP}^+/\text{NADPH}$  ratios, should be explored in the whole methionine cycle and special attention should be paid on subcellular distribution. The number of enzymes of this pathway found in the nucleus is increasing (SAHH, GNMT, MATs) and their role in this compartment is underexplored. Possibilities such as moonlighting activities cannot be forgotten, neither the protein-protein interactions in which they might be involved.

## 6. CONCLUSION

In the last 20 years our group has developed protocols and tools for the study of MATs and the methionine cycle and, as a result of this effort, new data have been obtained both *in vitro* and *in vivo*. Altogether, these results have shown the existence of new levels of regulation for MATs that might be key for understanding their role in disease, but which could also be considered as putative targets for the development of new treatments. Moreover, some aspects uncovered during our work might be useful as biomarkers of disease, provided the adequate tissue

samples and tools are available. In the near future, work in this field will require a larger effort on the solution of structures, the role of post-translational modifications, the identification of protein-protein interactions and development of imaging techniques able to evaluate subcellular levels of metabolites. Null mice models are valuable tools for the development of the field, but certain aspects concerning the proteins themselves cannot be analyzed in animals that lack their expression. Subcellular localization and its relationship with pathology lay within this category.

## 7. ACKNOWLEDGEMENTS

The work reviewed in this manuscript has been supported by grants of the Ministerio de Economía y Competitividad (PB94-0087, PM97-0064, BMC2002-00243, BMC2005-00050, BFU2008-00666/BMC, BFU2009-08977/BMC) and Fondo de Investigación Sanitaria (FIS 01/1077, C03/08, PI05/0563).

## 8. REFERENCES

1. Cantoni GL. Activation of methionine for transmethylation. *J Biol Chem* 1951; 189: 745-54.
2. Cantoni GL. S-adenosylmethionine; a new intermediate formed enzymatically from L-methionine and



- adenosinetriphosphate. *J Biol Chem* 1953; 204: 403-16.
3. Fontecave M, Atta M, Mulliez E. S-adenosylmethionine: nothing goes to waste. *Trends Biochem Sci* 2004; 29: 243-9.
4. Pajares MA, Markham GD. Methionine adenosyltransferase (s-adenosylmethionine synthetase). *Adv Enzymol Relat Areas Mol Biol* 2011; 78: 449-521.
5. Markham GD, Pajares MA. Structure-function relationships in methionine adenosyltransferases. *Cell Mol Life Sci* 2009; 66: 636-48.
6. Sufrin JR, Finckbeiner S, Oliver CM. Marine-derived metabolites of S-adenosylmethionine as templates for new anti-infectives. *Mar Drugs* 2009; 7: 401-34.
7. Konze JR, Kende H. Interactions of Methionine and Selenomethionine with Methionine Adenosyltransferase and Ethylene-generating Systems. *Plant Physiol* 1979; 63: 507-10.
8. Frey PA, Hegeman AD, Ruzicka FJ. The Radical SAM Superfamily. *Crit Rev Biochem Mol Biol* 2008; 43: 63-88.
9. Mato JM, Alvarez L, Ortiz P, Pajares MA. S-adenosylmethionine synthesis: molecular mechanisms and clinical implications. *Pharmacol Ther* 1997; 73: 265-80.
10. Aguilar TS, Benevenga NJ, Harper AE. Effect of dietary methionine level on its metabolism in rats. *J Nutr* 1974; 104: 761-71.
11. Zeisel SH, Wurtman RJ. Dietary intake of methionine: Influence of brain S-adenosylmethionine. In: Usdin E, Borchardt RT, Creveling CR, Eds. *Transmethylation*. New York: Elsevier 1979; pp. 59-68.
12. Martinez-Vega R, Garrido F, Partearroyo T, *et al.* Folic acid deficiency induces premature hearing loss through mechanisms involving cochlear oxidative stress and impairment of homocysteine metabolism. *FASEB J* 2015; 29: 418-32.
13. Lu SC, Mato JM. S-adenosylmethionine in liver health, injury, and cancer. *Physiol Rev* 2012; 92: 1515-42.
14. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. *Am J Pathol* 1969; 56: 111-28.
15. Ueland PM, Refsum H. Plasma homocysteine, a risk factor for vascular disease: plasma levels in health, disease, and drug therapy. *J Lab Clin Med* 1989; 114: 473-501.
16. Hooijmans CR, Blom HJ, Oppenraaij-Emmerzaal D, Ritskes-Hoitinga M, Kiliaan AJ. S-adenosylmethionine and S-adenosylhomocysteine levels in the aging brain of APP/PS1 Alzheimer mice. *Neurol Sci* 2009; 30: 439-45.
17. Panza F, Frisardi V, Capurso C, *et al.* Possible role of S-adenosylmethionine, S-adenosylhomocysteine, and polyunsaturated fatty acids in predementia syndromes and Alzheimer's disease. *J Alzheimers Dis* 2009; 16: 467-70.
18. Popp J, Lewczuk P, Linnebank M, *et al.* Homocysteine Metabolism and Cerebrospinal Fluid Markers for Alzheimer's Disease. *J Alzheimers Dis* 2009; 18: 819-28.
19. Refsum H, Helland S, Ueland PM. Fasting plasma homocysteine as a sensitive parameter of antifolate effect: a study of psoriasis patients receiving low-dose methotrexate treatment. *Clin Pharmacol Ther* 1989; 46: 510-20.
20. Delgado M, Perez-Miguelsanz J, Garrido F, *et al.* Early effects of copper accumulation on methionine metabolism. *Cell Mol Life Sci* 2008; 65: 2080-90.
21. Medici V, Shibata NM, Kharbanda KK, *et al.* Maternal choline modifies fetal liver copper, gene expression, DNA methylation, and neonatal growth in the tx-j mouse model of Wilson disease. *Epigenetics* 2014; 9: 286-96.
22. Shimizu K, Abe M, Yokoyama S, *et al.* Decreased activities of S-adenosylmethionine synthetase isozymes in hereditary hepatitis in Long-Evans rats. *Life Sci* 1990; 46: 1837-42.
23. Martinez-Vega R, Partearroyo T, Vallecillo N, Varela-Moreiras G, Pajares MA, Varela-Nieto I. Long-term omega-3 fatty acid supplementation prevents expression changes in cochlear homocysteine metabolism and ameliorates progressive hearing loss in C57BL/6J mice. *J Nutr Biochem* 2015; doi: 10.1016/j.jnutbio.2015.07.011.
24. Mueller JH. A new sulphur-containing amino acid isolated from hydrolytic products of protein. *J Biol Chem* 1923; 56: 157-69.
25. Womack M, Kemmerer KS, Rose WC. The relation of dietary methionine and cysteine to growth. *J Biol Chem* 1937; 121: 403-10.
26. Pajares MA, Perez-Sala D. Betaine homocysteine S-methyltransferase: just a regulator of homocysteine metabolism? *Cell Mol Life Sci* 2006; 63: 2792-803.
27. Szegedi SS, Castro CC, Koutmos M, Garrow TA. Betaine-homocysteine S-methyltransferase-2 is an S-methylmethionine-homocysteine methyltransferase. *J Biol Chem* 2008; 283: 8939-45.
28. Chen NC, Yang F, Capecci LM, *et al.* Regulation of homocysteine metabolism and methylation in human and mouse tissues. *FASEB J* 2010; 24: 2804-17.
29. Mudd SH, Finkelstein JD, Irreverre F, Laster L. Transsulfuration in mammals. Microassays and tissue distributions of three enzymes of the pathway. *J Biol Chem* 1965; 240: 4382-92.
30. Finkelstein JD. Metabolic regulatory properties of S-adenosylmethionine and S-adenosylhomocysteine. *Clin Chem Lab Med* 2007; 45: 1694-9.
31. Ou X, Yang H, Ramani K, *et al.* Inhibition of human betaine-homocysteine methyltransferase expression by

- S-adenosylmethionine and methylthioadenosine. *Biochem J* 2007; 401: 87-96.
32. Castro C, Breksa API, Salisbury EM, Garrow TA. Betaine-homocysteine S-methyltransferase (BHMT) transcription is inhibited by S-adenosylmethionine (AdoMet). In: Milstien S, Kapatos G, Levine RA, Shane B, Eds. *Chemistry and Biology of Pteridines and Folates*. Norwell: Kluwer 2001; pp. 549-56.
33. Martinez-Chantar ML, Vazquez-Chantada M, Garnacho M, *et al.* S-adenosylmethionine regulates cytoplasmic HuR via AMP-activated kinase. *Gastroenterology* 2006; 131: 223-32.
34. Jencks DA, Mathews RG. Allosteric inhibition of methylenetetrahydrofolate reductase by adenosylmethionine. Effects of adenosylmethionine and NADPH on the equilibrium between active and inactive forms of the enzyme and on the kinetics of approach to equilibrium. *J Biol Chem* 1987; 262: 2485-93.
35. Luka Z, Mudd SH, Wagner C. Glycine N-methyltransferase and regulation of S-adenosylmethionine levels. *J Biol Chem* 2009; 284: 22507-11.
36. Kery V, Bukovska G, Kraus JP. Transsulfuration depends on heme in addition to pyridoxal 5'-phosphate. Cystathionine beta-synthase is a heme protein. *J Biol Chem* 1994; 269: 25283-8.
37. Brown FC, Hudgins WR, Roszell JA. Reactions of cyclic amino acid derivatives with the pyridoxal phosphate of cystathionase. *J Biol Chem* 1969; 244: 2809-15.
38. Huennekens FM, DiGirolamo PM, Fujii K, Jacobsen DW, Vitols KS. B12 -- dependent methionine synthetase as a potential target for cancer chemotherapy. *Adv Enzyme Regul* 1976; 14: 187-205.
39. Gonzalez MP, Varela-Moreiras G, Selhub J, Paul L, Pajares MA. Methionine adenosyltransferase expression depends on methionine concentrations in the culture media. *Ann Nutr Metab* 2013; 63: 1342.
40. Gil B, Pajares MA, Mato JM, Alvarez L. Glucocorticoid regulation of hepatic S-adenosylmethionine synthetase gene expression. *Endocrinology* 1997; 138: 1251-8.
41. Pajares MA, Duran C, Corrales F, Pliego MM, Mato JM. Modulation of rat liver S-adenosylmethionine synthetase activity by glutathione. *J Biol Chem* 1992; 267: 17598-605.
42. Corrales F, Ochoa P, Rivas C, Martin-Lomas M, Mato JM, Pajares MA. Inhibition of glutathione synthesis in the liver leads to S-adenosyl-L-methionine synthetase reduction. *Hepatology* 1991; 14: 528-33.
43. Martinez-Chantar ML, Pajares MA. Role of thioltransferases on the modulation of rat liver S-adenosylmethionine synthetase activity by glutathione. *FEBS Lett* 1996; 397: 293-7.
44. Avila MA, Mingorance J, Martinez-Chantar ML, *et al.* Regulation of rat liver S-adenosylmethionine synthetase during septic shock: role of nitric oxide. *Hepatology* 1997; 25: 391-6.
45. Sanchez-Gongora E, Ruiz F, Mingorance J, An W, Corrales FJ, Mato JM. Interaction of liver methionine adenosyltransferase with hydroxyl radical. *FASEB J* 1997; 11: 1013-9.
46. Gonzalez B, Garrido F, Ortega R, *et al.* NADP(+) Binding to the Regulatory Subunit of Methionine Adenosyltransferase II Increases Intersubunit Binding Affinity in the Hetero-Trimer. *PloS ONE* 2012; 7: e50329.
47. Li Y, Chen J, Liu J, Yang X, Wang K. Binding of Cu<sup>2+</sup> to S-adenosyl-L-homocysteine hydrolase. *J Inorg Biochem* 2004; 98: 977-83.
48. Zou CG, Banerjee R. Homocysteine and redox signaling. *Antioxid Redox Signal* 2005; 7: 547-59.
49. Sanchez-Perez GF, Bautista JM, Pajares MA. Methionine adenosyltransferase as a useful molecular systematics tool revealed by phylogenetic and structural analyses. *J Mol Biol* 2004; 335: 693-706.
50. Lu ZJ, Markham GD. Enzymatic properties of S-adenosylmethionine synthetase from the archaeon *Methanococcus jannaschii*. *J Biol Chem* 2002; 277: 16624-31.
51. Yang H, Ara AI, Magilnick N, *et al.* Expression pattern, regulation, and functions of methionine adenosyltransferase 2beta splicing variants in hepatoma cells. *Gastroenterology* 2008; 134: 281-91.
52. Cabrero C, Puerta J, Alemany S. Purification and comparison of two forms of S-adenosyl-L-methionine synthetase from rat liver. *Eur J Biochem* 1987; 170: 299-304.
53. Mingorance J, Alvarez L, Pajares MA, Mato JM. Recombinant rat liver S-adenosyl-L-methionine synthetase tetramers and dimers are in equilibrium. *Int J Biochem Cell Biol* 1997; 29: 485-91.
54. Alvarez L, Mingorance J, Pajares MA, Mato JM. Expression of rat liver S-adenosylmethionine synthetase in *Escherichia coli* results in two active oligomeric forms. *Biochem J* 1994; 301: 557-61.
55. Halim AB, LeGros L, Geller A, Kotb M. Expression and functional interaction of the catalytic and regulatory subunits of human methionine adenosyltransferase in mammalian cells. *J Biol Chem* 1999; 274: 29720-5.
56. Kotb M, Geller AM. Methionine adenosyltransferase: structure and function. *Pharmacol Ther* 1993; 59: 125-43.
57. Lopez-Vara MC, Gasset M, Pajares MA. Refolding and characterization of rat liver methionine adenosyltransferase from *Escherichia coli* inclusion bodies. *Prot Expr Purif* 2000; 19: 219-26.
58. Gasset M, Alfonso C, Neira JL, Rivas G, Pajares MA. Equilibrium unfolding studies of the rat liver methionine adenosyltransferase III, a dimeric enzyme

- with intersubunit active sites. *Biochem J* 2002; 361: 307-15.
59. Gonzalez B, Pajares MA, Hermoso JA, *et al.* The crystal structure of tetrameric methionine adenosyltransferase from rat liver reveals the methionine-binding site. *J Mol Biol* 2000; 300: 363-75.
60. Gonzalez B, Pajares MA, Hermoso JA, Guillerm D, Guillerm G, Sanz-Aparicio J. Crystal structures of methionine adenosyltransferase complexed with substrates and products reveal the methionine-ATP recognition and give insights into the catalytic mechanism. *J Mol Biol* 2003; 331: 407-16.
61. Daigner HP, Mato JM, Pajares MA. Study of the rat liver S-adenosylmethionine synthetase active site with 8-azido ATP. *Biochem J* 1995; 308: 565-71.
62. Sanchez-Perez GF, Gasset M, Calvete JJ, Pajares MA. Role of an intrasubunit disulfide in the association state of the cytosolic homo-oligomer methionine adenosyltransferase. *J Biol Chem* 2003; 278: 7285-93.
63. Pajares MA, Corrales FJ, Ochoa P, Mato JM. The role of cysteine-150 in the structure and activity of rat liver S-adenosyl-L-methionine synthetase. *Biochem J* 1991; 274: 225-9.
64. Mingorance J, Alvarez L, Sanchez-Gongora E, Mato JM, Pajares MA. Site-directed mutagenesis of rat liver S-adenosylmethionine synthetase. Identification of a cysteine residue critical for the oligomeric state. *Biochem J* 1996; 315: 761-6.
65. Avila MA, Corrales FJ, Ruiz F, *et al.* Specific interaction of methionine adenosyltransferase with free radicals. *BioFactors* 1998; 8: 27-32.
66. Martinez-Chantar ML, Pajares MA. Assignment of a single disulfide bridge in rat liver methionine adenosyltransferase. *Eur J Biochem* 2000; 267: 132-7.
67. Iloro I, Chehin R, Goni FM, Pajares MA, Arrondo JL. Methionine adenosyltransferase alpha-helix structure unfolds at lower temperatures than beta-sheet: a 2D-IR study. *Biophys J* 2004; 86: 3951-8.
68. Houry WA, Frishman D, Eckerskorn C, Lottspeich F, Hartl FU. Identification of in vivo substrates of the chaperonin GroEL. *Nature* 1999; 402:147-54.
69. Pajares MA, Pérez C. The relationship between human MAT1A mutations and disease: a folding and association problem? In: Walters EC, ed. *Protein Folding*. New York: Nova Science Publishers 2011; pp. 261-87.
70. Mudd SH. Hypermethioninemias of genetic and non-genetic origin: A review. *Am J Med Genet C Semin Med Genet* 2011; 157C: 3-32.
71. Chien YH, Abdenur JE, Baronio F, *et al.* Mudd's disease (MAT I/III deficiency): a survey of data for MAT1A homozygotes and compound heterozygotes. *Orphanet J Rare Dis* 2015; 10: 99.
72. Chamberlin ME, Ubagai T, Mudd SH, Levy HL, Chou JY. Dominant inheritance of isolated hypermethioninemia is associated with a mutation in the human methionine adenosyltransferase 1A gene. *Am J Human Genet* 1997; 60: 540-6.
73. Chamberlin ME, Ubagai T, Mudd SH, *et al.* Methionine adenosyltransferase I/III deficiency: novel mutations and clinical variations. *Am J Human Genet* 2000; 66:347-55.
74. Hazelwood S, Bernardini I, Shotelersuk V, *et al.* Normal brain myelination in a patient homozygous for a mutation that encodes a severely truncated methionine adenosyltransferase I/III. *Am J Human Genet* 1998; 75: 395-400.
75. Gasso M, Rubio M, Varela G, *et al.* Effects of S-adenosylmethionine on lipid peroxidation and liver fibrogenesis in carbon tetrachloride-induced cirrhosis. *J Hepatol* 1996; 25: 200-5.
76. Corrales F, Gimenez A, Alvarez L, *et al.* S-adenosylmethionine treatment prevents carbon tetrachloride-induced S-adenosylmethionine synthetase inactivation and attenuates liver injury. *Hepatology* 1992; 16: 1022-7.
77. Shafqat N, Muniz JR, Pilka ES, *et al.* Insight into S-adenosylmethionine biosynthesis from the crystal structures of the human methionine adenosyltransferase catalytic and regulatory subunits. *Biochem J* 2013; 452: 27-36.
78. Murray B, Antonyuk SV, Marina A, *et al.* Structure and function study of the complex that synthesizes S-adenosylmethionine. *IUCrJ* 2014; 1: 240-9.
79. Avila MA, Berasain C, Torres L, *et al.* Reduced mRNA abundance of the main enzymes involved in methionine metabolism in human liver cirrhosis and hepatocellular carcinoma. *J Hepatol* 2000; 33: 907-14.
80. Huang ZZ, Mato JM, Kanel G, Lu SC. Differential effect of thioacetamide on hepatic methionine adenosyltransferase expression in the rat. *Hepatology* 1999; 29: 1471-8.
81. Lu SC, Alvarez L, Huang ZZ, *et al.* Methionine adenosyltransferase 1A knockout mice are predisposed to liver injury and exhibit increased expression of genes involved in proliferation. *Proc Natl Acad Sci USA* 2001; 98: 5560-5.
82. Chamberlin ME, Ubagai T, Mudd SH, Wilson WG, Leonard JV, Chou JY. Demyelination of the brain is associated with methionine adenosyltransferase I/III deficiency. *J Clin Invest* 1996; 98: 1021-7.
83. Reytor E, Perez-Miguelsanz J, Alvarez L, Perez-Sala D, Pajares MA. Conformational signals in the C-terminal domain of methionine adenosyltransferase I/III determine its nucleocytoplasmic distribution. *FASEB J* 2009; 23: 3347-60.
84. Robbins J, Dilworth SM, Laskey RA, Dingwall C. Two interdependent basic domains in nucleoplasmic nuclear targeting sequence: identification of a class of bipartite nuclear targeting sequence. *Cell* 1991; 64: 615-23.

85. Sessler RJ, Noy N. A ligand-activated nuclear localization signal in cellular retinoic acid binding protein-II. *Mol Cell* 2005; 18: 343-53.
86. Turpin P, Ossareh-Nazari B, Dargemont C. Nuclear transport and transcriptional regulation. *FEBS Lett* 1999; 452: 82-6.
87. Katoh Y, Ikura T, Hoshikawa Y, *et al.* Methionine Adenosyltransferase II Serves as a Transcriptional Corepressor of Maf Oncoprotein. *Mol Cell* 2011; 41: 554-66.
88. Gibson BA, Kraus WL. Small molecules, big effects: a role for chromatin-localized metabolite biosynthesis in gene regulation. *Mol Cell* 2011; 41: 497-9.
89. Cabrero C, Duce AM, Ortiz P, Alemany S, Mato JM. Specific loss of the high-molecular-weight form of S-adenosyl-L-methionine synthetase in human liver cirrhosis. *Hepatology* 1988; 8: 1530-4.
90. Stramentinoli G, Gualano M, Ideo G. Protective role of S-adenosyl-L-methionine on liver injury induced by D-galactosamine in rats. *Biochem Pharmacol* 1978; 27: 1431-3.
91. Friedel HA, Goa KL, Benfield P. S-adenosyl-L-methionine. A review of its pharmacological properties and therapeutic potential in liver dysfunction and affective disorders in relation to its physiological role in cell metabolism. *Drugs* 1989; 38: 389-416.
92. Schnackenberg LK, Chen M, Sun J, *et al.* Evaluations of the trans-sulfuration pathway in multiple liver toxicity studies. *Toxicol Appl Pharmacol* 2009; 235: 25-32.
93. Delgado M, Garrido F, Perez-Miguelsanz J, *et al.* Acute liver injury induces nucleocytoplasmic redistribution of hepatic methionine metabolism enzymes. *Antioxid Redox Signal* 2014; 20: 2541-54.
94. Baillie TA, Rettie AE. Role of biotransformation in drug-induced toxicity: influence of intra- and inter-species differences in drug metabolism. *Drug Metab Pharmacokinet* 2011; 26: 15-29.
95. Shiraki N, Shiraki Y, Tsuyama T, *et al.* Methionine metabolism regulates maintenance and differentiation of human pluripotent stem cells. *Cell Metab* 2014; 19: 780-94.
96. Gil B, Casado M, Pajares MA, *et al.* Differential expression pattern of S-adenosylmethionine synthetase isoenzymes during rat liver development. *Hepatology* 1996; 24: 876-81.
97. Pajares MA, Alvarez L, Perez-Sala D. How are mammalian methionine adenosyltransferases regulated in the liver? A focus on redox stress. *FEBS Lett* 2013; 587: 1711-6.
98. Pajares MA, Corrales F, Duran C, Mato JM, Alvarez L. How is rat liver S-adenosylmethionine synthetase regulated? *FEBS Lett* 1992; 309: 1-4.